CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy

Nano Today(2022)

Cited 24|Views22
No score
Abstract
•A selective responsiveness accelerated gene delivery system was constructed.•The gene delivery system rendered tumor-specific CD47 knockout and engineered tumor cells into factories of IL-12.•Combination of CD47 blockade and IL-12 production synergistically promoted the macrophage-mediated immunotherapy.
More
Translated text
Key words
CD47 blockade,IL-12 production,Selective responsiveness accelerated gene delivery system,TAM polarization,CRISPR/Cas9
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined